‘Smart’ lens could predict risk of glaucoma progression

A new study reveals how a “smart” contact lens can help identify which patients with glaucoma – a leading cause of blindness – are most likely to experience disease progression.
Dr. C. Gustavo De Moraes, an associate professor of ophthalmology at Columbia University Medical Center (CUMC) in New York, NY, and colleagues reveal the success of the novel technology in the journal Ophthalmology.
Glaucoma is a term for a group of conditions characterized by damage to the eye’s optic nerve, which can lead to vision loss.
According to the Glaucoma Research Foundation, more than 3 million Americans have glaucoma, and around 120,000 people are blind from the disease. Worldwide, glaucoma is the second leading cause of blindness.
Open-angle glaucoma is the most common form, accounting for around 90% of all cases. This is where the drainage canals of the eye become blocked over time, causing a rise in eye pressure that damages the optic nerve.
Currently, disease progression among patients with glaucoma is monitored through comprehensive routine eye examinations, in which an eye doctor will assess the patient’s eye pressure.
Researchers say the smart lens could help doctors identify which glaucoma patients are at high risk for disease progression.”
However, Dr. De Moraes and colleagues note that such tests can only provide snapshot information from a single point in time. Additionally, eye pressure is most likely to rise at night, and current tests are impractical to perform at this time.
But there may be a solution to this problem: a contact lens with a built-in sensor that can monitor eye pressure 24 hours a day.

Smart lens data identified patients with fast glaucoma progression

For their study, the researchers tested the contact lens – called Sensimed Triggerfish – on 40 patients aged 40-89 who were undergoing treatment for open-angle glaucoma.
Over 2 years, each patient underwent at least eight comprehensive eye exams, which were used to determine glaucoma progression. At the end of the 2 years, 20 of the patients were identified as having slow disease progression, while the remaining 20 had fast disease progression……..
Read more: http://www.medicalnewstoday.com/articles/306141.php
Source: Medical News Today